Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MS Morgan Stanley	$148.61 +0.6%	$139.68	$94.09 ▼ $149.08	$235.87B	1.32	5.10 million shs	4.19 million shs
PFE Pfizer	$25.12 -0.2%	$24.56	$20.92 ▼ $30.43	$143.05B	0.52	45.97 million shs	32.46 million shs
VALE Vale	$9.91 -1.7%	$9.80	$8.06 ▼ $12.05	$45.75B	0.74	48.36 million shs	23.32 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MS Morgan Stanley	+0.53%	+5.41%	+4.91%	+12.52%	+49.45%
PFE Pfizer	-0.10%	+3.59%	+1.99%	+10.03%	-12.96%
VALE Vale	-1.59%	-0.90%	+2.27%	+1.12%	-2.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MS Morgan Stanley	4.7748 of 5 stars	2.2	4.0	4.2	2.4	3.3	2.5	2.5
PFE Pfizer	4.9633 of 5 stars	3.2	3.0	4.2	4.5	3.2	1.7	3.1
VALE Vale	3.8648 of 5 stars	2.3	5.0	3.3	0.0	3.4	0.0	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MS Morgan Stanley	2.47	Hold	$138.25	-6.97% Downside
PFE Pfizer	2.39	Hold	$28.12	11.96% Upside
VALE Vale	2.50	Moderate Buy	$11.84	19.58% Upside

Current Analyst Ratings Breakdown

Latest MS, PFE, and VALE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	PFE Pfizer	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$25.00 ➝ $26.00
8/6/2025	PFE Pfizer	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$32.00 ➝ $33.00
8/6/2025	PFE Pfizer	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$27.00 ➝ $28.00
8/4/2025	VALE Vale	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$9.00 ➝ $10.00
7/22/2025	VALE Vale	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$13.00 ➝ $12.50
7/9/2025	MS Morgan Stanley	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$127.00 ➝ $160.00
7/8/2025	MS Morgan Stanley	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$120.00 ➝ $145.00
7/2/2025	VALE Vale	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$12.75 ➝ $13.00
6/18/2025	MS Morgan Stanley	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$125.00 ➝ $130.00
6/10/2025	MS Morgan Stanley	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$121.00 ➝ $136.00
5/29/2025	PFE Pfizer	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold	$28.00 ➝ $25.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MS Morgan Stanley	$107.29B	2.21	$11.58 per share	12.83	$62.34 per share	2.38
PFE Pfizer	$63.63B	2.24	$4.35 per share	5.77	$15.66 per share	1.60
VALE Vale	$38.06B	1.18	$2.34 per share	4.23	$8.92 per share	1.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MS Morgan Stanley	$13.39B	$8.83	16.83	15.76	1.85	13.06%	15.20%	1.15%	10/15/2025 (Estimated)
PFE Pfizer	$8.03B	$1.88	13.36	8.29	0.90	16.84%	21.42%	9.12%	N/A
VALE Vale	$6.17B	$1.23	8.05	4.69	N/A	14.23%	18.14%	7.99%	10/23/2025 (Estimated)

Latest MS, PFE, and VALE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
7/31/2025	Q2 2025	VALE Vale	$0.34	$0.50	+$0.16	$0.50	$9.54 billion	$8.80 billion
7/16/2025	Q2 2025	MS Morgan Stanley	$1.98	$2.13	+$0.15	$2.13	$16.15 billion	$16.79 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MS Morgan Stanley	$4.00	2.69%	N/A	45.30%	12 Years
PFE Pfizer	$1.72	6.85%	N/A	91.49%	16 Years
VALE Vale	$0.72	7.27%	N/A	58.54%	N/A

Latest MS, PFE, and VALE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/4/2025	VALE Vale	semi-annual	$0.3417	7.4%	8/13/2025	8/13/2025	9/10/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
7/18/2025	MS Morgan Stanley	quarterly	$1.00	2.6%	7/31/2025	7/31/2025	8/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MS Morgan Stanley	3.30	0.78	0.78
PFE Pfizer	0.65	1.16	0.85
VALE Vale	0.48	1.22	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MS Morgan Stanley	84.19%
PFE Pfizer	68.36%
VALE Vale	21.85%

Insider Ownership

Company	Insider Ownership
MS Morgan Stanley	0.19%
PFE Pfizer	0.06%
VALE Vale	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MS Morgan Stanley	80,000	1.60 billion	1.59 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
VALE Vale	64,610	4.54 billion	4.54 billion	Optionable

MS, PFE, and VALE Headlines

Recent News About These Companies

BofA Securities Affirms ‘Buy’ Rating on Vale S.A. (VALE)

August 14 at 9:46 PM | finance.yahoo.com

GQG Partners LLC Buys Shares of 37,252,302 Vale S.A. (NYSE:VALE)

August 14 at 7:39 AM | marketbeat.com

Vale S.A. (NYSE:VALE) Shares Sold by Mondrian Investment Partners LTD

August 14 at 6:15 AM | marketbeat.com

Deutsche Bank AG Decreases Position in Vale S.A. (NYSE:VALE)

August 14 at 4:00 AM | marketbeat.com

UBS Lifts PT on Vale S.A. (VALE) to $10 From $9, Keeps a Neutral Rating

August 13 at 12:17 AM | insidermonkey.com

Vale S.A. Files SEC Report to Maintain Regulatory Compliance

August 13 at 12:05 PM | msn.com

Vale Target of Unusually Large Options Trading (NYSE:VALE)

August 13 at 2:15 AM | americanbankingnews.com

Todd Asset Management LLC Increases Stock Position in Vale S.A. (NYSE:VALE)

August 12 at 7:53 AM | marketbeat.com

Longfellow Investment Management Co. LLC Acquires 89,307 Shares of Vale S.A. (NYSE:VALE)

August 12 at 7:44 AM | marketbeat.com

LPL Financial LLC Purchases 115,979 Shares of Vale S.A. (NYSE:VALE)

August 11, 2025 | marketbeat.com

Analysts Set Vale S.A. (NYSE:VALE) Price Target at $11.84

August 11, 2025 | americanbankingnews.com

Vale S.A. (NYSE:VALE) Shares Bought by Connor Clark & Lunn Investment Management Ltd.

August 10, 2025 | marketbeat.com

Zurcher Kantonalbank Zurich Cantonalbank Sells 68,682 Shares of Vale S.A. (NYSE:VALE)

August 10, 2025 | marketbeat.com

Davis Selected Advisers Makes New $27.28 Million Investment in Vale S.A. (NYSE:VALE)

August 9, 2025 | marketbeat.com

Vale S.A. (NYSE:VALE) Shares Acquired by US Bancorp DE

August 9, 2025 | marketbeat.com

Cetera Investment Advisers Takes Position in Vale S.A. (NYSE:VALE)

August 9, 2025 | marketbeat.com

Vale S.A. Files SEC Report for August 2025

August 8, 2025 | tipranks.com

Vale S.A. (NYSE:VALE) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 8, 2025 | marketbeat.com

BHP, Vale offer $1.4 billion settlement in UK lawsuit over Brazil dam disaster, FT reports

August 7, 2025 | reuters.com

Vale S.A. (NYSE:VALE) Shares Sold by Fourth Sail Capital LP

August 7, 2025 | marketbeat.com

Vale S.A. (NYSE:VALE) Shares Acquired by Scotia Capital Inc.

August 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MS, PFE, and VALE Company Descriptions

Morgan Stanley NYSE:MS

$148.61 +0.85 (+0.58%)

Closing price 08/14/2025 03:59 PM Eastern

Extended Trading

$148.49 -0.13 (-0.08%)

As of 04:19 AM Eastern

Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals in the Americas, Europe, the Middle East, Africa, and Asia. It operates through Institutional Securities, Wealth Management, and Investment Management segments. The Institutional Securities segment offers capital raising and financial advisory services, including services related to the underwriting of debt, equity, and other securities, as well as advice on mergers and acquisitions, restructurings, real estate, and project finance. This segment also provides equity and fixed income products comprising sales, financing, prime brokerage, and market-making services; foreign exchange and commodities; corporate and commercial real estate loans, commercial mortgage and secured lending facilities, and financing for sales and trading customers, and asset-backed and mortgage lending; and wealth management services, investment, and research services. The Wealth Management segment offers financial advisor-led brokerage, custody, administrative, and investment advisory services; self-directed brokerage services; financial and wealth planning services; workplace services, including stock plan administration; annuity and insurance products; securities-based lending, residential real estate loans, and other lending products; banking; and retirement plan services to individual investors and small to medium-sized businesses and institutions. The Investment Management segment provides equity, fixed income, alternatives and solutions, and liquidity and overlay services to benefit/defined contribution plans, foundations, endowments, government entities, sovereign wealth funds, insurance companies, third-party fund sponsors, corporations, and individuals through institutional and intermediary channels. The company was founded in 1924 and is headquartered in New York, New York.

Pfizer NYSE:PFE

$25.12 -0.05 (-0.18%)

Closing price 08/14/2025 03:59 PM Eastern

Extended Trading

$25.15 +0.04 (+0.14%)

As of 04:38 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Vale NYSE:VALE

$9.90 -0.18 (-1.74%)

Closing price 08/14/2025 03:59 PM Eastern

Extended Trading

$9.99 +0.09 (+0.91%)

As of 04:33 AM Eastern

Vale S.A., together with its subsidiaries, produces and sells iron ore and iron ore pellets for use as raw materials in steelmaking in Brazil and internationally. The company operates through Iron Solutions and Energy Transition Materials segments. The Iron Solutions segment produces and extracts iron ore and pellets, manganese, and other ferrous products; and provides related logistic services. The Energy Transition Materials segment produces and extracts nickel used to produce stainless steel, electric vehicles, and metal alloys; and its by-products, such as gold, silver, cobalt, precious metals, platinum, and others, as well as copper used in the construction sector to produce pipes and electrical wires. The company was formerly known as Companhia Vale do Rio Doce and changed its name to Vale S.A. in May 2009. Vale S.A. was founded in 1942 and is headquartered in Rio de Janeiro, Brazil.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time